These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 17616089)

  • 1. This paper continues Professor Adaikan's distinguished involvement in classical pharmacologic research of erectile physiology.
    Pickard R
    Eur Urol; 2007 Jul; 52(1):259-60. PubMed ID: 17616089
    [No Abstract]   [Full Text] [Related]  

  • 2. Mechanisms of action of PDE5 inhibition in erectile dysfunction.
    Corbin JD
    Int J Impot Res; 2004 Jun; 16 Suppl 1():S4-7. PubMed ID: 15224127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Commentary on apomorphine versus sildenafil for erectile dysfunction.
    Carson CC
    J Urol; 2008 May; 179(5 Suppl):S95-6. PubMed ID: 18405768
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy of PDE-5-inhibitors for erectile dysfunction. A comparative meta-analysis of fixed-dose regimen randomized controlled trials administering the International Index of Erectile Function in broad-spectrum populations.
    Rosen RC; Shaw JW
    Int J Impot Res; 2006; 18(6):570-1; author reply 572-3. PubMed ID: 17075585
    [No Abstract]   [Full Text] [Related]  

  • 5. Commentary on adjunctive use of testosterone gel with sildenafil for erectile dysfunction.
    Morales A
    J Urol; 2008 May; 179(5 Suppl):S103. PubMed ID: 18405738
    [No Abstract]   [Full Text] [Related]  

  • 6. Nitric oxide regulation of penile erection: biology and therapeutic implications.
    Burnett AL
    J Androl; 2002; 23(5):S20-6. PubMed ID: 12236169
    [No Abstract]   [Full Text] [Related]  

  • 7. Phosphodiesterase-5 inhibition: the molecular biology of erectile function and dysfunction.
    Francis SH; Corbin JD
    Urol Clin North Am; 2005 Nov; 32(4):419-29, vi. PubMed ID: 16291034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emergence and success of PDE5 inhibitors as effective therapy for erectile dysfunction.
    Manganiello V
    Int J Impot Res; 2004 Jun; 16 Suppl 1():S1-3. PubMed ID: 15224126
    [No Abstract]   [Full Text] [Related]  

  • 9. First-line therapies for erectile dysfunction.
    Ensign C
    JAAPA; 2001 Oct; 14(10):17-20. PubMed ID: 11715672
    [No Abstract]   [Full Text] [Related]  

  • 10. Optimisation of PDE5 inhibitor therapy in men with erectile dysfunction: converting "non-responders" into "responders".
    Eardley I
    Eur Urol; 2006 Jul; 50(1):31-3. PubMed ID: 16517052
    [No Abstract]   [Full Text] [Related]  

  • 11. Salvage techniques for phosphodiesterase 5 inhibitor therapy: purposeful but how much?
    Burnett AL
    Eur Urol; 2006 Jul; 50(1):29-30. PubMed ID: 16567036
    [No Abstract]   [Full Text] [Related]  

  • 12. SAR development of polycyclic guanine derivatives targeted to the discovery of a selective PDE5 inhibitor for treatment of erectile dysfunction.
    Pissarnitski DA; Asberom T; Boyle CD; Chackalamannil S; Chintala M; Clader JW; Greenlee WJ; Hu Y; Kurowski S; Myers J; Palamanda J; Stamford AW; Vemulapalli S; Wang Y; Wang P; Wu P; Xu R
    Bioorg Med Chem Lett; 2004 Mar; 14(5):1291-4. PubMed ID: 14980684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Some aspects of erectile dysfunction pathogenesis and treatment in patients with obesity].
    Ametov AS; Teodorovich OV; Kondrat'eva LV; Popova AIu
    Ter Arkh; 2006; 78(2):92-4. PubMed ID: 16613108
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmacology of erectile dysfunction in man.
    Cirino G; Fusco F; Imbimbo C; Mirone V
    Pharmacol Ther; 2006 Aug; 111(2):400-23. PubMed ID: 16443277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclic GMP and phosphodiesterase 5 inhibitor therapies: what's on the horizon?
    Lincoln TM
    Mol Pharmacol; 2004 Jul; 66(1):11-3. PubMed ID: 15213291
    [No Abstract]   [Full Text] [Related]  

  • 16. Rationale for androgens and erectile dysfunction in 2006.
    Roumeguère T
    Eur Urol; 2006 Nov; 50(5):898-900. PubMed ID: 16893603
    [No Abstract]   [Full Text] [Related]  

  • 17. Phosphodiesterase 5 mechanisms and therapeutic applications.
    Burnett AL
    Am J Cardiol; 2005 Dec; 96(12B):29M-31M. PubMed ID: 16387563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of DA-8159, a novel PDE5 inhibitor, on erectile function in the rat model of hypercholesterolemic erectile dysfunction.
    Kang KK; Yu JY; Yoo M; Kwon JW
    Int J Impot Res; 2005; 17(5):409-16. PubMed ID: 15920460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review of time of onset and duration of clinical efficacy of phosphodiesterase type 5 inhibitors in treatment of erectile dysfunction.
    Shabsigh R; Seftel AD; Rosen RC; Porst H; Ahuja S; Deeley MC; Garcia CS; Giuliano F
    Urology; 2006 Oct; 68(4):689-96. PubMed ID: 17070333
    [No Abstract]   [Full Text] [Related]  

  • 20. Phosphodiesterase type 5 inhibitors for erectile dysfunction.
    Carson CC; Lue TF
    BJU Int; 2005 Aug; 96(3):257-80. PubMed ID: 16042713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.